Abstract
Summary This is the first double-blind, placebo-controlled study showing that vaccination with recombinant hypoallergenic allergen-derivatives is safe and induces sustained allergen-specific IgG responses which block allergic patients IgE binding to the allergen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have